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Abstract
Chlamydiae are obligate intracellular bacteria that propagate in a cytosolic vacuole. Recent work has shown that growth of
Chlamydia induces the fragmentation of the Golgi apparatus (GA) into ministacks, which facilitates the acquisition of host
lipids into the growing inclusion. GA fragmentation results from infection-associated cleavage of the integral GA protein,
golgin-84. Golgin-84-cleavage, GA fragmentation and growth of Chlamydia trachomatis can be blocked by the peptide
inhibitor WEHD-fmk. Here we identify the bacterial protease chlamydial protease-like activity factor (CPAF) as the factor
mediating cleavage of golgin-84 and as the target of WEHD-fmk-inhibition. WEHD-fmk blocked cleavage of golgin-84 as
well as cleavage of known CPAF targets during infection with C. trachomatis and C. pneumoniae. The same effect was seen
when active CPAF was expressed in non-infected cells and in a cell-free system. Ectopic expression of active CPAF in non-
infected cells was sufficient for GA fragmentation. GA fragmentation required the small GTPases Rab6 and Rab11
downstream of CPAF-activity. These results define CPAF as the first protein that is essential for replication of Chlamydia.W e
suggest that this role makes CPAF a potential anti-infective therapeutic target.
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Introduction
Chlamydiae are a group of obligate intracellular bacteria that
infect humans and animals. Chlamydia trachomatis is the most
common bacterial agent of sexually transmitted disease with a
prevalence of up to about 5% in young women as well as a common
cause of eye infections. Clinically, the most relevant aspect of
infection with C. trachomatis is its propensity for chronic infection,
which may lead to female infertility and to blinding trachoma
[1,2,3]. Chlamydia pneumoniae is a very common cause of (typically
mild) airwayinfection butit has also been proposed to cause chronic
infection of artery walls, contributing to atherosclerosis [4].
During its developmental cycle Chlamydia switches between two
morphologically distinguishable forms. The infectious but meta-
bolically inactive elementary body (EB) is taken up by the host cell,
where it resides in the cytosol, within a membranous vacuole,
termed the inclusion. Within the inclusion EBs differentiate into
reticulate bodies (RBs), which divide by binary fission. During this
intracellular growth phase the inclusion substantially increases in
size, often filling almost the entire cell at later time points.
Towards the end of the cycle RBs re-differentiate into EBs, which
are subsequently released from the cell. In vitro this cycle takes
approximately 2 days for C. trachomatis and 3-4 days for C.
pneumoniae [5].
To be able to grow, Chlamydia must escape cellular defenses and
acquire nutrients and macromolecules from the host cell. In
particular, trafficking of host lipids to the chlamydial inclusion has
been noted where they are probably required for the expanding
lipid membrane of the growing inclusion as well as for bacterial
membranes [6,7,8]. Numerous alterations of other host cell
systems have also been described during infection, including
massive changes in gene transcription, cytoskeletal rearrangement
and the inhibition of apoptosis [9]. Although molecular details
often remain unclear these changes are probably mainly the result
of the translocation of bacterial effectors into the host cytosol.
Chlamydia possesses a type III secretion system and a number of
bacterial proteins have been described to be secreted into the
inclusion membrane or beyond [10,11]. One chlamydial protease,
chlamydial protease-like activity factor (CPAF), is known to
translocate from the inclusion to the cytosol approximately mid-
cycle [12]. Several host cell proteins have been identified as
proteolytic targets of CPAF although the immediate relevance of
such cleavage events for the development of the infection has not
been established [13].
PLoS Pathogens | www.plospathogens.org 1 September 2011 | Volume 7 | Issue 9 | e1002283We recently identified the fragmentation of the Golgi apparatus
(GA) as a consequence of infection with C. trachomatis [14,15]. This
fragmentation coincides with the cleavage of an integral GA
matrix protein, golgin-84, and can be phenocopied by silencing of
golgin-84 by RNAi. Intriguingly, golgin-84-cleavage can be
inhibited by a modified tetrapeptide, z-WEHD-fmk (WEHD-
fmk) [14], and WEHD-fmk blocks the replication of C. trachomatis
[14,16]. Conversely, silencing of golgin-84 enhances bacterial
replication [14]. This strongly suggests that the cleavage of golgin-
84 during infection causes fragmentation of the GA and that this
fragmentation is required for chlamydial growth, most likely
because it facilitates transport of essential lipids to the inclusion.
Here we identify CPAF as the chlamydial protease responsible
for golgin-84-cleavage and as the target of WEHD-fmk during
infection. WEHD-fmk, which has been developed as an inhibitor
of caspase-1 is shown to inhibit CPAF-activity in a number of
experimental situations. When expressed ectopically in human
cells, CPAF is found to cause the fragmentation of the GA.
Chlamydia thus depends on the secretion of CPAF into the host cell
to ensure its intracellular growth. Targeting this individual
bacterial protease can prevent replication of Chlamydia in human
cells.
Results
WEHD-fmk inhibits growth and development of
pathogenic Chlamydia
We have previously shown that WEHD-fmk-treatment dramat-
ically (several hundredfold) inhibits the generation of infectious EB
during cell culture infection with C. trachomatis [14]. Confocal
analysis confirmed that development of C. trachomatis was strongly
reduced and inclusions were reduced in size when cultures were
treated with WEHD-fmk (Fig. 1A).
We also determined that WEHD-fmk inhibits the growth of a
chlamydial species distinct from C. trachomatis, C. pneumoniae. As
shown in Fig. 1B, WEHD-fmk substantially inhibited growth and
development of C. pneumoniae in infected epithelial cells. In C.
pneumoniae infection WEHD-fmk impaired the production of
infectious EBs more than 10-fold at 3 days post-infection (d p.i.)
(Fig. 1B, left panel) although this effect was not quite as striking as
in the case of C. trachomatis (see [14]). Genome copy number was
measured at 48 h (following WEHD-fmk addition at 24 h) and
was found to be about 4-fold reduced (Fig. 1B, bottom panel).
Inhibitor treatment was also demonstrated to impede the fusion
of individual, smaller bacterial inclusions to larger inclusions
during C. pneumoniae infection (Fig. 1C). During acute C. pneumoniae
infection the chlamydial protease CPAF is secreted from the
inclusion into the cytosol approximately mid-cycle [17]. We
analysed CPAF localisation in C. pneumoniae infected cells 3 d p.i.b y
confocal microscopy and found that secretion of CPAF was
blocked when cells were cultured in the presence of WEHD-fmk
(Fig. 1C). An unusual, patchy staining pattern for CPAF was
observed inside the inclusions in the presence of WEHD-fmk,
whereas inhibitor treatment did not affect lipopolysaccharide
(LPS) staining pattern. This suggests that less CPAF is secreted
from the chlamydial inclusion into the host cell during C. pneumonia
infection (Fig. 1C) (we used C. pneumoniae here because we were
able to obtain better staining with the antibodies available to us in
this species). As will become clear below, all of this probably
reflects the general growth inhibition imposed by WEHD-fmk.
WEHD-fmk blocks Chlamydia-dependent proteolytic
activity
As previously reported for infection with various C. trachomatis
strains [14], the infection with C. pneumoniae also caused the
cleavage of the GA matrix protein, golgin-84 (Fig. 2A). However,
the protease responsible for this degradation had not been
identified. We considered the participation of the chlamydial
protease CPAF mainly for two reasons. First, the time course of
golgin-84-cleavage during infection (beginning around mid-cycle)
correlates very well with the appearance of CPAF-activity [12,17].
Indeed, CPAF-mediated degradation of vimentin correlated well
with the degradation of golgin-84 during C. pneumoniae infection
(Fig. 2A and see below). Secondly, we observed that WEHD-fmk
not only inhibited the degradation of golgin-84 during C.
pneumoniae infection but also prevented the cleavage of the known
CPAF substrate vimentin (Fig. 2A).
To gain an overview of WEHD-fmk-specificity we tested a
number of related tetrapeptide inhibitors. Screening of a library of
inhibitors, which has been designed to inhibit various caspases,
showed that among these modified peptides WEHD-fmk had the
strongest CPAF-inhibitory effect in the cell-free assay (using
recombinant CPAF) while two inhibitors, VEID-fmk and LEVD-
fmk, came close in terms of inhibitory potential (Fig. S1A; we here
used as a source of active CPAF 293T cells where CPAF had been
activated by dimerisation; Text S1; [18] and see below). Others
(for instance DEVD-fmk and LEHD-fmk; also YVAD-fmk, which
has like WEHD-fmk been devised as a caspase-1-inhibitor) had no
detectable activity. Closer investigation of some of the inhibitors
showed that VEID-fmk was comparable to WEHD-fmk in the
cell-free system (Fig. S1B; Text S1) and showed some, although
less marked, activity in inhibiting CPAF-dependent cleavage inside
human cells (Fig. S1C) or growth of Chlamydia (Fig. S1E, Text S1),
most likely due to different cell-permeability.
We had previously found that a calpain inhibitor also blocked
Chlamydia-mediated degradation of golgin-84 [14]. This inhibitor
was also active in inhibiting CPAF-mediated vimentin cleavage in
T-Rex-293-gyrB-CPAF cells (Fig. S1C). When tested during
infection, LEHD-fmk and DEVD-fmk were inactive in inhibiting
CPAF-mediated cleavage of vimentin or bacterial growth (Fig.
S1D, E). This suggests that during chlamydial infection WEHD-
fmk acts by targeting CPAF rather than a caspase.
For a closer analysis of the link between WEHD-fmk and CPAF
we returned to the C. trachomatis cell culture infection model.
Author Summary
Chlamydiae are bacteria that replicate only inside host (for
instance human) cells and that are frequent agents of
human disease, in particular sexually transmitted disease.
Chlamydia lives in a vacuole inside the cell, surrounded by
a lipid membrane, and must acquire nutrients and other
factors from the host cell for its replication and for the
growth of the vacuole. Recent results show that for this,
Chlamydia relies on its ability to induce the loss of an
individual protein of the Golgi apparatus (a cellular
structure that sorts materials for transport in the cell)
called golgin-84. In this work we find that Chlamydia does
this using its protein-cleaving enzyme CPAF (which is
made by Chlamydia and transported from the vacuole into
the cell). CPAF cleaves golgin-84 and thereby induces
changes in the Golgi apparatus that are linked to the
acquisition of some cellular material by Chlamydia.W e
further show that a synthetic inhibitor, which was recently
found to block chlamydial growth, does that by inhibiting
CPAF. CPAF therefore seems necessary for chlamydial
growth and blocking CPAF may be a therapeutic strategy
against infections with Chlamydia.
Inhibition of CPAF
PLoS Pathogens | www.plospathogens.org 2 September 2011 | Volume 7 | Issue 9 | e1002283Figure 1. WEHD-fmk inhibits chlamydial growth. (A) WEHD-fmk inhibits the development of C. trachomatis. HeLa cells were infected with C.
trachomatis (MOI=2). At indicated time points cells were fixed, stained for bacterial Hsp60 (green) and analysed by confocal microscopy. Overlay with
the phase contrast is shown. Scale bars, 10 mm. (B) WEHD-fmk reduces infectious progeny of C. pneumoniae in cell culture. Top: HEp-2 cells were
infected with C. pneumoniae (MOI=3). At 24 h p.i., WEHD-fmk or DMSO (solvent control) was added. Cell aliquots were harvested each day to a
maximum of 96 h p.i. and infectious EBs were enumerated by titration on fresh host cell monolayers. Data are mean/SEM from three independent
experiments. **, p-value , 0.05 (Students t-test). As WEHD-fmk was only added at 24 h, there is no value for cultures with the inhibitor at this point.
Bottom: Genome copy number does not change after WEHD treatment. Hep2 cells were infected with C. pneumoniae using an MOI of 3. WEHD
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84 but also the cleavage of the CPAF-substrates vimentin,
cytokeratin-8 (CK8), cyclin B1 and RFX5 [13,18] (Fig. 2B).
Remarkably, WEHD-fmk also reduced the detectable levels of
active CPAF (Fig. 2B). This is probably the consequence of a
feedback-loop: since WEHD-fmk blocks the growth of Chlamydia,
fewer bacteria develop in the cells and this reduces the total
production of CPAF. Addition of CPAF also blocked the
appearance of the strong anti-apoptotic effect that Chlamydia
establishes in infected cells (i.e. in the presence of WEHD-fmk
infected cells remained sensitive to staurosporine while they
became resistant in its absence as reported before [19]; data not
shown). In the presence of WEHD-fmk, there was a modest
reduction in the amounts of chlamydial proteins, as assessed by
probing Western blots with Chlamydia-reactive antisera from
human patients (Fig. 2C), suggesting inhibition of growth or
development. This inhibition very likely also leads to the defects in
CPAF secretion and chlamydial development (see above).
WEHD-fmk targets CPAF
These data were suggestive of a link between growth inhibition
of Chlamydia by WEHD-fmk and CPAF. Possible mechanisms of
the observed effects included the reduced secretion of CPAF from
the vacuole to the cytosol and the direct inhibition of CPAF by
WEHD-fmk. It could also not be excluded at this stage that the
loss of CPAF activity was secondary to a different inhibitory
mechanism of WEHD-fmk.
To distinguish between these possibilities we used a system for
the ectopic expression of active CPAF in human cells. As reported
earlier, CPAF can be activated in the absence of infection by the
experimental dimerisation of CPAF (through the dimerisation of
its fusion partner gyrase B (gyrB), which is achieved by the dimeric
gyrB ligand coumermycin (CM) [18]). We utilised a system based
on the human cell line 293T, which stably carries a tetracycline-
inducible gyrB-C. trachomatis-CPAF construct (the cells are
designated T-REx-293-gyrB-CPAF). Addition of anhydrotetracy-
cline (AHT, a tetracycline-derivative lacking antibiotic activity)
and CM to these cells induces CPAF-activation as measured as
autocatalytic cleavage and cleavage of all known CPAF-substrates
[18].
Expression of active CPAF in T-REx-293-gyrB-CPAF cells
caused the cleavage of vimentin as reported earlier (Fig. 3A) [18].
With a similar time course golgin-84 was degraded to fragments
that were indistinguishable from those generated during chlamyd-
ial infection (Fig. 3A) suggesting that CPAF was responsible for the
cleavage of golgin-84 in both situations. Addition of WEHD-fmk
at the time of CPAF-induction prevented the cleavage of golgin-84
as well as the degradation of the known CPAF-substrates (Fig. 3B,
C). Lactacystin, which is known to inhibit both the human
proteasome and CPAF [12,20], also reduced cleavage of the
CPAF-substrates tested while a specific inhibitor of the proteasome
(epoxomicin) had no effect (Fig. 3C).
WEHD-fmk has been developed as an inhibitor of caspase-1.
Since caspase-1-activation during infection of HeLa cells has
recently been demonstrated in Chlamydia infected cells [16], it was
also a possibility that part of the effect of WEHD-fmk was due to
caspase-1 inhibition. We have above shown evidence that WEHD-
fmk is not acting by inhibiting a caspase, and the evidence is
overwhelming that the CPAF-dependent cleavage of the host cell
proteins tested (vimentin, CK8, RFX5, cyclin B1) does not depend
on caspase-1 [12,13,18,20,21,22]. The pan-caspase-inhibitor z-
VAD-fmk further failed to inhibit the tested cleavage events
(Fig. 3C), excluding the possibility that WEHD-fmk acted by
inhibition of caspases in this system.
These results suggested that WEHD-fmk acted as an inhibitor of
CPAF. This notion is further supported by the finding that
WEHD-fmk also blocked the morphological effects that CPAF
produces when expressed in T-REx-293-gyrB-CPAF cells
(Fig.S2A; Text S1) at concentrations that blocked cleavage of
vimentin (Fig. S2B). In a cell-free assay, lysate from AHT/CM-
induced T-REx-293-gyrB-CPAF cells (i.e. lysate containing active
CPAF) degraded myc-tagged CK8 (separately expressed by
transfection of 293T cells); this cleavage was inhibited by
WEHD-fmk and lactacystin (Fig. 3D). Further, bacterial lysate
containing active recombinant CPAF degraded the substrates
vimentin and CK8 in lysates from human cells and this cleavage
was again inhibited by WEHD-fmk (Fig. S3A, B; Text S1). Thus,
cleavage of all tested proteins that are known to be cleaved in a
CPAF-dependent way during infection was inhibited by WEHD-
fmk. Further, the cleavage of the same proteins was also blocked
by WEHD-fmk when active CPAF was expressed in human cells,
as was the cleavage of vimentin and CK8 by bacterial re-
combinant CPAF. This makes it very unlikely that another
protease was involved and strongly suggests that WEHD-fmk
acted as an inhibitor of chlamydial CPAF.
We have shown previously that most of the inhibitory effect of
WEHD-fmk is reversed when golgin-84 is knocked down,
suggesting that the effect of the inhibitor is limited to preventing
the cleavage of golgin-84 (and therefore to inhibiting CPAF [14]).
Inhibition of chlamydial replication by WEHD-fmk is therefore
very likely due to CPAF inhibition and not effects on additional
targets.
Ectopically expressed active CPAF causes GA
fragmentation, dependent on Rab6A and Rab11A
As reported previously, Chlamydia causes the fragmentation of
the GA to ensure its replication, very likely because this facilitates
lipid transport to the bacterial inclusion [14,15]. Since GA
fragmentation is linked to the cleavage of golgin-84 and golgin-84-
cleavage is the result of CPAF-activity, CPAF-activity may be
expected to be responsible for the fragmentation of the GA during
infection. Indeed, the isolated expression of active CPAF induced
GA fragmentation in T-REx-293-gyrB-CPAF cells (Fig. S4; Text
S1) as well as in HeLa cells transiently expressing the gyrB-CPAF
expression construct (Fig.4). The presence of WEHD-fmk during
expression of active CPAF prevented GA fragmentation as
expected (Fig. 4, Fig. S4).
We have recently shown that Chlamydia-induced GA fragmen-
tation requires the small GTPases Rab6A and Rab11A [15]. If
CPAF is responsible for GA fragmentation, this effect of CPAF is
expected also to depend on Rab6 and Rab11. We tested this
prediction and found that indeed the reduction of either Rab6 or
Rab11 by RNAi had a clear inhibitory effect on GA fragmentation
induced by the expression of active CPAF in HeLa cells (Fig. 5)
treatment (80 mM) was started 24h post infection. 2 days post infection, genome copy numbers were compared by quantitative real time PCR. (C)
Localisation of C. pneumoniae CPAF in the presence of WEHD. HEp-2 cells were infected with C. pneumoniae (MOI=3). 24 h p.i. cells were treated with
80 mM WEHD-fmk or DMSO. On day 3 cells were fixed and CPAF (green channel) and bacterial LPS (red channel) were visualized with specific
antibodies. Samples were analysed by confocal laser scanning microscopy. Overlays of the two fluorescence channels and phase contrast are shown.
C shows higher magnification of the boxed area. Scale bars, 10 mM.
doi:10.1371/journal.ppat.1002283.g001
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PLoS Pathogens | www.plospathogens.org 4 September 2011 | Volume 7 | Issue 9 | e1002283Figure 2. WEHD-fmk inhibits CPAF-dependent cleavage events during infection with Chlamydia. (A) Inhibition of proteolysis during
infection with C. pneumoniae. HEp-2 cells were infected with C. pneumoniae (MOI=3). 24 h p.i. either 80 mM WEHD-FMK (+) or DMSO (-) were added.
Cells were collected and lysed 24, 48 and 72 h p.i.. Uninfected cells were harvested after 24 h. Golgin-84, vimentin and bacterial Hsp60 were detected
in lysates by immunoblotting. F, specific cleavage products. (B) Inhibition of proteolysis during infection with C. trachomatis. T-REx-293 cells were
Inhibition of CPAF
PLoS Pathogens | www.plospathogens.org 5 September 2011 | Volume 7 | Issue 9 | e1002283while knock-down per se did not affect GA morphology (Fig. S5;
Text S1) [15].
Taken together, these results provide strong evidence that
CPAF is the enzyme that cleaves golgin-84 and thereby
contributes to GA fragmentation, which in turn is linked to lipid
transport to the chlamydial inclusion. WEHD-fmk blocks CPAF
activity, interrupting these events and inhibiting normal chlamyd-
ial growth.
Discussion
These results establish a link between the production of CPAF
by Chlamydia, the cleavage of golgin-84 and subsequent GA
fragmentation, which again is required for efficient chlamydial
replication. CPAF activity is thus indispensable for the intracel-
lular replication and development of Chlamydia, and the targeting
of CPAF may be a strategy to reduce the burden of chlamydial
infection.
WEHD-fmk blocked the degradation of all known and
investigated CPAF substrates when recombinant CPAF was tested
in cell extracts and when active CPAF was expressed in human
cells. This suggests a direct binding of the inhibitor to the protease.
Although the protease has been crystallised together with its
known inhibitor lactacystin, the great width of the active site
makes it difficult to predict how this inhibitory mechanism might
work. The differences in inhibitory potential of other peptide
inhibitors tested suggest a binding of individual amino acids from
the inhibitor sequence. There is no clearly defined substrate
recognition and cleavage sequence of CPAF. The possibility
should also be considered that substrate recognition of CPAF
occurs at a site distinct from the actual cleavage site. If that was the
case, WEHD-fmk might bind at a domain outside the active site of
the protease.
During infection, WEHD-fmk not only inhibits CPAF-depen-
dent substrate cleavage but also growth of Chlamydia, as already
reported earlier [14]. This is linked to the cleavage of golgin-84
and the subsequent GA fragmentation. CPAF has a high number
of known substrates [13] and very likely many more that have not
been identified. All of these substrates may have an effect on
chlamydial growth. However, the cleavage of golgin-84 may be of
particular importance. As we have found earlier, knock-down of
golgin-84 (inducing GA fragmentation) reverses the inhibitory
effect of WEHD-fmk to a considerable extent [14]. As cleavage of
all other CPAF substrates is presumably still blocked by the
inhibitor in this situation, these cleavage events may not be critical,
at least in cell culture.
The group of chlamydiae and Chlamydia-related bacteria are
very widespread and successful as infectious agents of many
diverse species throughout the animal kingdom [23]. The forms of
related bacteria range from organisms that have been isolated as
symbionts of free-living amoebae (for instance Protochlamydia
amoebophila [24]) over agents that parasitize amoebae but may
also infect humans (Parachlamydia acanthamoebae [25]) to a number of
species that frequently infect animal (such as C. caviae, C. abortus)
and human hosts (C. trachomatis, C. pneumoniae, C. psittaci). All of
these bacterial species share the lifestyle of intracellular develop-
ment in a membranous cytosolic inclusion. This developmental
peculiarity carries the advantage of a degree of protection against
host cell defense systems afforded by the lipid membrane, and
probably makes it easier to generate a specialised environment for
optimal replication. It is however also associated with the
requirement of arranging for vacuole growth by continuous
substitution of lipids as well as the acquisition of lipids and
nutrients from the host cell for bacterial growth.
Sphinogmyelin acquisition by the chlamydial inclusion occurs
both early (within hours of infection) and late in the developmental
cycle, and has been linked to multivesicular bodies and to
interception of post-Golgi traffic [7,8,26]. We have recently found
that fragmentation of the GA facilitates this transport at later
stages of infection [14]. The results shown here suggest that this
late sphingolipid acquisition is the result of CPAF activity, which
may be an important aspect of the function of this protease in
chlamydial intracellular development.
Identifiable CPAF-orthologs have been found in Chlamydia-
related organisms as distant from human pathogens as P.
amoebophila [24]. This suggests that CPAF indeed serves a function
that is indispensable to the lifestyle of these organisms. It is at least
conceivable (although highly speculative at this stage) that the
function in vesicle acquisition that we identify here during
infection of human cells with C. trachomatis was an original
function of CPAF already in Chlamydia-related organisms parasit-
izing amoebae.
Acute chlamydial infections can be easily and successfully
treated with antibiotics and although antibiotic resistance may
develop this is not a major problem at this stage. The biggest
problem clinically concerns chronic infections. At least in vitro,
chlamydiae can enter a persistent state that likely reflects chronic
infection and during which Chlamydia is resilient to antibiotic
treatment [27]. We cannot say whether Chlamydia also depends on
CPAF for the maintenance of a chronic infection but it is
intriguing that serum antibodies to CPAF are characteristic of
long-term infections in humans [28], suggesting that CPAF is
indeed expressed during chronic infection. The inhibition of
CPAF, the principal feasibility of which is shown here, may
therefore turn out to be a valuable approach to the therapy of
human chlamydial infection.
Materials and Methods
Cell lines and culture
The human embryonic kidney cell line T-REx-293, which
stably expresses the tetracycline repressor (Invitrogen, Darmstadt,
Germany) was maintained in humidified air at 5% CO2 and 37uC
in Dulbecco modified Eagle `s minimal essential medium (DMEM)
supplemented with 10% fetal calf serum (FCS, tetracycline
negative; PAA Laboratories, Pasching, Austria) and 5 mg/ml
blasticidin (PAA Laboratories, Pasching, Austria). Stable, gyrB-
CPAF expressing T-REx-293 clones were generated by electro-
infected with C. trachomatis (MOI=2) for the time points indicated. The peptide inhibitor WEHD-fmk (75 mM) was added after 9 h of infection. Cell
extracts subjected to Western Blot analysis, probing for CPAF-substrates and CPAF. CPAF is expressed as an inactive precursor but is rapidly activated
by autocatalytic cleavage. The antiserum was raised against a peptide in the C-terminal fragment of CPAF. Shown is a representative result of three
independent experiments. *, non-specific background bands. F, CPAF specific cleavage products. CPAFc, C-terminal fragment of mature
(proteolytically processed) CPAF. Three individual blots with samples from the same experiment are shown (vimentin, CK8, CPAF, actin; cyclin B1,
RFX5, actin; golgin-84). (C) Assessment of chlamydial protein expression in the presence of WEHD-fmk. T-REx-293 cells were infected with C.
trachomatis (MOI=2) for the times indicated. The peptide inhibitor WEHD-fmk (75 mM) was added after 9 h of infection where stated. Cell extracts
were subjected to Western Blot analysis, using a mix of sera from five patients that had tested positive for antibodies to C. trachomatis antibodies by
routine clinical testing.
doi:10.1371/journal.ppat.1002283.g002
Inhibition of CPAF
PLoS Pathogens | www.plospathogens.org 6 September 2011 | Volume 7 | Issue 9 | e1002283poration with the pcDNA4/TO/myc-His-gyrB-CPAF (C. trachoma-
tis CPAF) construct and subjected to antibiotic selection as
previously reported [18]. The cells were cultured as above but
in the presence of zeocin (350 mg/ml; InvivoGen, San Diego, CA,
USA). To induce and activate CPAF 5 ng/ml anhydrotetracycline
(AHT; IBA, Go ¨ttingen, Germany) and 1 mM coumermycin (CM;
Sigma-Aldrich, Steinbach, Germany) were added. HeLa and
HEp-2 cells were grown in DMEM supplemented with 10% fetal
calf serum but lacking blasticidin and zeocin. WEHD-fmk (R&D
Systems, Wiesbaden-Nordenstedt, Germany), z-VAD-fmk (Ba-
Figure 3. WEHD-fmk is an inhibitor of CPAF-dependent proteolysis. (A) CPAF cleaves golgin-84. Active CPAF was expressed in T-REx-293-
gyrB-CPAF cells. For this, cells were stimulated with AHT for 16 h to express CPAF-precursor. The CM was added to activate CPAF. At the time points
indicated after CM addition, cells were harvested, lysed and golgin-84 and vimentin were detected by immunoblotting. F, CPAF specific cleavage
products. (B) WEHD-fmk blocks degradation of golgin-84 and RFX5 in T-REx-293-gyrB-CPAF cells. Cells were either treated simultaneously with AHT/
CM for 12 h to activate CPAF or were left untreated. CPAF-activity was inhibited by 80 mM WEHD-fmk or DMSO was added. Cell extracts were
prepared and probed for the proteins indicated. *, non-specific background band. F, CPAF specific cleavage products. (C) Inhibition profile of golgin-
84 degradation. T-REx-293-gyrB-CPAF cells were treated with WEHD-fmk (75 mM), lactacystin (25 mM), the proteasome inhibitor epoxomicin (2.5 mM)
or the pan-caspase inhibitor z-VAD-fmk (75 mM) prior to CPAF-induction and activation (by AHT/CM for 18 h). Cell extracts were prepared and
subjected to Western Blot analysis. Shown is a representative result of four independent experiments. F, CPAF specific cleavage products. (D)
Inhibition of CPAF-activity by WEHD-fmk in a cell-free system. Cell extracts of T-REx-293-gyrB-CPAF cells and T-REx-293 cells expressing myc-tagged
cytokeratin 8 (CK8-myc) were combined in the presence of either WEHD-fmk (75 mM) or lactacystin (40 mM) and incubated for 60 min at 37uC.
Reactions were analyzed by Western blotting. A-C: Shown is a representative result of three independent experiments. F, proteolytic product. LC,
lactacystin. Epox, epoxomicin. zVAD, zVAD-fmk.
doi:10.1371/journal.ppat.1002283.g003
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stadt, Germany) or Clasto-lactacystin b-lactone (Sigma-Aldrich,
Steinbach, Germany) were added as indicated.
Chlamydial infection
The C. trachomatis strain (serovar L2) was obtained from the
American Type Culture Collection (ATCC). For infection of T-
REx-293 or HeLa cells, the culture medium was replaced with
serum free medium without antibiotics and bacteria were added
using the specified multiplicity of infection (MOI). Two hours later
the medium was supplemented with 10% FCS. C. pneumoniae strain
VR1310 was a kind gift of Dr. Gunnar Christiansen (Institute of
Medical Microbiology and Immunology, University of Aarhus,
Denmark). Prior to infection, culture medium was removed and C.
pneumoniae was added in DMEM containing 1 mg/ml cyclohexi-
mide. The cells were then centrifuged at 2,000 g for 35 min at
35uC and further cultivated for the times indicated.
Immunoblotting
Cell extracts were prepared using RIPA-buffer (1% Triton X-
100, 0.5% SDS, 0.5% deoxycholate, 1 mM EDTA, 150 mM
NaCl, and 50 mM Tris, pH 8.0) supplemented with a protease
inhibitor cocktail (Roche, Mannheim, Germany). Proteins were
separated by SDS-PAGE and transferred onto nitrocellulose
membranes. Antibodies used were directed against b-actin
(Sigma-Aldrich, Steinbach, Germany), chlamydial Hsp60 (Alexis
Biochemicals, San Diego, CA, USA), Bim, cyclin B1, myc (all from
Cell Signaling Technology, Beverly, MA, USA), CK8, RFX5,
Figure 4. CPAF causes Golgi-complex fragmentation. Transiently expressed CPAF causes Golgi fragmentation in epithelial cells. HeLa cells
were either cotransfected with constructs coding for gyrB-CPAF and pCMV-eGFP (CPAF + GFP) or transfected with the GFP-construct only (GFP). CPAF
was induced and activated 4h post transfection by adding AHT/CM and WEHD (75 mM) was added at the same time (+WEHD). Fragmentation of the
Golgi apparatus was analyzed 48 h post induction by staining of the GA matrix protein GPP130. Left: GPP130 staining; middle: GFP expression, right:
merged images. Scale bars, 20 mM.
doi:10.1371/journal.ppat.1002283.g004
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Bioscience, Heidelberg, Germany) and CPAF (a polyclonal serum
generated by immunization of rabbits with a peptide from the C-
terminal fragment of C. trachomatis CPAF; Pineda Antibody-
Service, Berlin, Germany). Antibodies specific for C. pneumoniae
CPAF were a generous gift of Dr. Guangming Zhong (San
Antonio, Texas, USA). In one series of experiments, Western blots
were probed with human sera from patients that had tested
Figure 5. CPAF-induced Golgi fragmentation is Rab6A- and Rab11A-dependent in HeLa cells transiently expressing active CPAF. (A)
HeLa cells were depleted for Rab6A, Rab11A by transfection with specific siRNAs. Luciferase-specific siRNA was used as a control. 48 h post
transfection of the siRNAs, an expression construct for gyrB-CPAF was cotransfected with pCMV-eGFP. CPAF was induced and activated 4h post
transfection by adding AHT/CM. 48 h post transfection of CPAF- and GFP-vectors, cells were fixed and immunostained. Left: GPP130, middle: GFP
expression, right: merged images. Scale bar, 20 mm. (B) Expression of Rab6A and Rab11A after siRNA transfection. HeLa cells were transfected with
siRNAs specific for Rab6A, Rab11A or luciferase. Protein expression was assessed after 72 h by Western blotting.
doi:10.1371/journal.ppat.1002283.g005
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Munich, Germany). A mixture of five sera was used. Proteins were
visualized using peroxidase-conjugated secondary antibodies and a
chemoluminescence detection system (GE Healthcare, Uppsala,
Sweden).
Cell-free proteolysis assay
As a source of active CPAF, T-REx-293-gyrB-CPAF cells were
stimulated with AHT/CM for 18 h and lysed in NP-40 buffer (1%
NP-40, 150 mM NaCl, 1 mM EDTA, and 20 mM MOPS,
pH 7.4). Cell extracts were mixed with equal volumes of lysate
from T-REx-293 cells transiently transfected with a myc-tagged
CK8-construct. Reactions were incubated at 37uC for 1 h and
subjected to Western blot analysis. Clasto-lactacystin b-lactone or
WEHD-fmk was added 30 min prior to substrate addition.
RNA interference
siRNAs were purchased from QIAGEN (QIAGEN, Hilden,
Germany). HeLa cells were seeded into 12-well plates one day
before transfection. Transfection was performed using QIAGEN
RNAiFect according to the manufacturer’s guidelines. 1 mg siRNA
was added to 96 ml Opti-MEM medium (Invitrogen, Darmstadt,
Germany), vortexed, mixed with 6 ml RNAiFect and incubated for
15 min at room temperature. The liposome/RNA mix was added
to cells with 600 ml growth medium [15]. After 24 h, cells were
trypsinised and seeded into new cell culture plates and incubated
for another 24 h.
Immunofluorescence and confocal microscopy
Cells were seeded onto coverslips and treated as indicated. Cells
were then fixed with 2% PFA for 30 min at room temperature.
The Golgi marker GPP130 (Covance, Princeton, NJ, USA) as well
as CPAF were detected using specific antibodies. Bacteria were
stained using either a chlamydial LPS specific antibody (Milan
Analytica AG) or a chlamydial Hsp60 specific antibody (Alexis
Biochemicals, San Diego, CA, USA). Binding was visualized using
fluorescence labeled secondary antibodies. Cells were mounted in
Mowiol. For the localisation of CPAF, HeLa cells were infected
with C. pneumoniae VR1310 (MOI=3) and WEHD-fmk (80 mM)
was added 24 h p.i. (DMSO was added in the controls). Fixation
was followed by treatment with 0.2% Triton X-100 in PBS
supplemented with 0.2% BSA. Cells were analysed with an LSCM
(Leica TCS SP-1, 63x/1.32 HCX PL APO CS oil lens, Leica
Microsystems, Wetzlar, Germany) and images were processed
using Adobe Photoshop.
Determination of C. pneumoniae genome copy numbers
Genome copy numbers were determined by real-time Light-
Cycler PCR as described previously [29]. Briefly, DNA extraction
was performed using NucleoSpin RNA/DNA according to the
manufacturer’s recommendations (Macherey-Nagel, Du ¨ren, Ger-
many): The 16S rRNA was amplified (forward primer, CAT CGT
TTA CGG CAA GGA CTA; reverse primer, AGG CCT TAG
GGT TGT AAA GCA). Absolute numbers of genome copies were
obtained by calculating the cp-values of the respective samples
against a standard curve (ten-fold dilutions of C. pneumoniae
infection inoculums) with known IFUs/ml.
Supporting Information
Figure S1 Peptide inhibitors vary in their efficacy in
inhibiting CPAF and chlamydial growth. (A) CPAF-
inhibitory activity of inhibitors in a cell-free system. Cell extracts
of T-REx-293-gyrB-CPAF cells and T-REx-293 cells expressing
myc-tagged cytokeratin 8 (CK8-myc) were combined in the
presence of lactacystin (LC, 40 mM), WEHD-fmk (75 mM) or
peptide-fmk inhibitors of a Caspase-Family Inhibitor Set (Promo-
kine, Heidelberg, Germany; 75 mM) and incubated for 60 min at
37uC. Reactions were analyzed by Western blotting. Shown is a
representative result of two independent experiments. (B) Activity
of recombinant CPAF is blocked by WEHD-fmk and VEID-fmk.
Purified, recombinant CPAF was combined with lysate of T-REx-
293 cells. Prior to the addition of CPAF substrate, WEHD-fmk or
VEID-fmk was added to CPAF for 30 min as indicated. Reactions
were incubated for 60 min at 37uC and analyzed by Western
blotting. Shown is a representative result of three independent
experiments. F, CPAF specific cleavage products. (C) VEID-fmk
and calpain inhibitor III block degradation of vimentin in T-REx-
293-gyrB-CPAF cells. Cells were treated with AHT/CM as
indicated either alone or in the presence of VEID-fmk (75 mM),
WEHD-fmk (75 mM) or calpain inhibitor III (100 mM; Calbio-
chem, Darmstadt, Germany). Cell extracts were prepared and
probed for vimentin. In all cases representative results of two
independent experiments are shown. In the bottom blot one lane
was removed digitally. F, CPAF specific cleavage products. (D)
WEHD- or VEID- but not LEHD- or DEVD-fmk inhibits CPAF-
dependent cleavage of vimentin during chlamydial infection. T-
REx-293 cells were infected with C. trachomatis (MOI=2) for 24 h.
WEHD-fmk, VEID-fmk, LEHD-fmk or DEVD-fmk (75 mM) were
added after 9 h of infection. Cell extracts were subjected to
Western blot analysis. Similar results were seen in three
experiments. In two further experiments, the effect of VEID-fmk
was smaller than that of WEHD-fmk. F, CPAF specific cleavage
products. Intensities of bands corresponding to full length or
cleaved protein were determined using the ImageJ software
(http://rsbweb.nih.gov/). Ratios of fragment to intact protein in
the various lanes are given below the blot. (E) WEHD- or VEID-
but not LEHD- or DEVD-fmk inhibits chlamydial growth. HeLa
cells were infected with C. trachomatis (MOI=2). Inhibitors (75 mM)
were added 8 h after infection. After 24 h cells were fixed, stained
for chlamydial MOMP and analyzed by confocal microscopy.
Overlay with the phase contrast is shown. Scale bar, 20 mm.
(TIF)
Figure S2 WEHD-fmk blocks the consequences of
CPAF-activity in CPAF expressing T-REx-293-gyrB-CPAF
cells. (A) WEHD-fmk suppresses CPAF-induced changes in cell
morphology. Expression and activation of CPAF was induced in
T-REx-293-gyrB-CPAF cells by addition of 5 ng/ml AHT and 1
mM CM for 18 h. WEHD-fmk, the pan-caspase inhibitor zVAD-
fmk (75 mM). Inhibitors were added 30 min prior to CPAF-
induction. Shown is a representative result of three independent
experiments. Scale bar, 50 mm. (B) WEHD-fmk prevents CPAF-
dependent vimentin-cleavage. T-REx-293-gyrB-CPAF cells were
treated as in (A), lysed and subjected to Western blot analysis.
Shown is a representative result of three independent experiments.
F, CPAF specific cleavage product.
(TIF)
Figure S3 CPAF-containing bacterial lysates exhibit
cleavage activity and WEHD sensitivity. (A) WEHD-fmk
inhibits cleavage activity of CPAF-containing bacterial lysate. As
above CPAF-containing E. coli extract was combined with lysates
of transiently transfected T-REx-293 cells (vim-GFP or CK8-myc).
Prior to the addition of CPAF substrate WEHD-fmk (100 mM) was
added for 30 min. Lysates were incubated for 30 min at 37uC and
analysed by Western blotting. Shown is a representative result of
three independent experiments. *, non-specific background band.
F, CPAF specific cleavage products. (B) CPAF-containing bacterial
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was combined with lysates of either vimentin-GFP (vim-GFP) or
CK8-myc expressing T-REx-293 cells and incubated for the time
points indicated at 37uC. Substrate cleavage was monitored by
Western blotting. Untransformed bacteria or E. coli transformed
with empty vector were used as controls. Shown is a representative
result of three independent experiments. *, non-specific back-
ground band. F, CPAF specific cleavage products.
(TIF)
Figure S4 WEHD-fmk inhibits Golgi fragmentation in
CPAF expressing cells. CPAF was induced and activated in T-
REx-293-gyrB-CPAF cells using AHT/CM (5 h). Another set of
cells were left untreated. WEHD-fmk (80 mM) was added at the
time of induction (+ WEHD). Cells were fixed and Golgi
fragmentation was analysed by GPP130 staining (red channel).
Cells were counterstained using the DRAQ 5 (blue channel). Left:
GPP130; center: DRAQ 5; right: merged images. Scale bar,
20 mm.
(TIF)
Figure S5 Depletion of Rab6A or Rab11A does not alter
GA morphology. HeLa cells were transfected with siRNA
specific for Rab6A, Rab11A or Luciferase. 48 h after siRNA
transfection, gyrB-CPAF and CMV-eGFP were cotransfected.
Cells were fixed and immunostained after an incubation of 48 h.
Left: GPP130; middle: GFP; right: merged images. Scale bar,
20 mM.
(TIF)
Text S1 Supporting Information: Experimental Proce-
dures.
(DOC)
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